Back

GLP-1 receptor agonists: the cardiovascular benefits beyond glucose control.

27 August 2018 (13:20 - 13:35)
Organised by:
Congress Presentation Part of: Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice? (EBAC Accredited) Risk Factors and Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Filip Krag Knop

Gentofte Hospital, University of Copenhagen, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
Introduction - Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice?
Professor T. Luescher (London, GB)
Presentation thumbnail
Diabetes and cardiovascular disease: time for a multifactorial approach.
Professor J. Deanfield (London, GB)
Presentation thumbnail
Translating GLP-1 trial outcomes to cardiology practice: which patients will benefit? .
Professor L. Ryden (Stockholm, SE)
Presentation thumbnail
Discussion and summary - Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice?
Professor J. Deanfield (London, GB) Professor T. Luescher (London, GB)

Access the full session

Session thumbnail
Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice? (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

27 August 2018 13:20 CET
You may be interested in
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Session
From risk factor management to treatment optimisation in patients with cardiac disease